GlassScriptPhysician profile
Pankaj Mehta
NPI 1558525154
$9,759.97
in general payments reported to CMS, 2019-2025
46 companies · $653 in 2025
The $653 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,217 · 2020: $1,681 · 2021: $1,410 · 2022: $1,324 · 2023: $2,161 · 2024: $313 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,840 · Consulting Fee: $200 · Education: $88.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,839.95 |
| Consulting Fee | $200.00 |
| Education | $88.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,980.39 | 2019-2023 | Breztri, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,193.94 | 2019-2023 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Glaxosmithkline, LLC. | $1,107.69 | 2019-2023 | Trelegy Ellipta |
| Abbott Laboratories | $840.78 | 2021-2025 | Proclaim, Eterna |
| Sunovion Pharmaceuticals INC. | $432.79 | 2019-2020 | |
| Grifols USA, LLC | $398.70 | 2019-2023 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $357.57 | 2020-2023 | Wakix |
| Bayer Healthcare Pharmaceuticals INC. | $350.81 | 2020-2023 | |
| Genzyme Corporation | $285.88 | 2019-2023 | |
| Mylan Specialty L.P. | $275.72 | 2019-2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $251.05 | 2019-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $244.39 | 2019-2023 | Zerbaxa, Recarbrio |
| Nevro Corp. | $243.30 | 2023 | Senza |
| Insmed, INC. | $174.07 | 2021-2023 | Arikayce |
| Noah Medical Corporation | $167.11 | 2024 | Galaxy |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.